Pharmacy Compounding Advisory Committee
Coverage of Pharmacy Compounding Advisory Committee in the Nexus archive.
- The Peptide Gold Rush Is Coming
BPC-157, a peptide rumored to treat various conditions, has gained popularity through influencers and Robert F. Kennedy Jr. An FDA advisory committee recommended allowing compounding pharmacies to produce it despite limited safety data. Telehealth companies may soon offer it if the FDA approves the recommendation.
- FDA panel overrules its own scientists to ease access to unproven peptide injections
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend four unproven peptides (BPC-157, KPV, TB-500, and MOTS-c) for access through compounding pharmacies, despite scientific concerns.
- FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to add peptides like BPC-157, KPV, TB-500, and MOTS-c to the list of substances compounding pharmacies can make, despite opposition from FDA scientists over concerns about their unproven benefits.
- FDA to review 7 popular peptides touted for weight loss, healing and longevity
The FDA is reviewing seven unapproved peptides for potential inclusion in compounded prescription drugs, with meetings scheduled for July 23-24. These peptides, popular for weight loss, wound healing, and other health claims, are widely available through clinics and online sellers despite lacking FDA approval. HHS Secretary Robert F. Kennedy Jr. supports expanding access, while FDA reviewers express concerns about safety and efficacy.